Kelly James Patrick 4/A

What Happened
Kelly James Patrick, Novavax (NVAX) EVP, Chief Financial Officer and Treasurer, was granted a derivative equity award for 194,000 shares on March 2, 2026. The grant is reported at $0.00 per share (no cash paid at grant). This was an award/other acquisition (Form 4 code A), not a sale—so it represents stock-based compensation/retention rather than a liquidity event.

Key Details

• Transaction date: 2026-03-02; reported on an amended Form 4/A filed 2026-03-09 (original Form 4 filed Mar 3, 2026).
• Grant amount: 194,000 shares; reported price: $0.00 (derivative).
• Vesting: 1/4 vests on the first anniversary of March 2, 2026; remaining 3/4 vest in equal monthly installments over the following 3 years, subject to continued employment (footnote F2).
• Amendment note: Form 4/A was filed solely to correct the exercise price and price of the derivative security as originally reported; all other information unchanged (footnote F1).
• Shares owned after the transaction are not specified in this filing.
• Filing timeliness: original Form 4 was filed promptly (Mar 3); this is an amendment to correct reported pricing—not a late trading disclosure.

Context
This was a time‑based equity award (a derivative grant), not an immediate sale or open‑market purchase. Such grants are typically part of executive compensation and vest over time to align incentives and retain the executive. The amendment affects the reported exercise/derivative price only; it does not change the number of shares granted or the vesting schedule.